The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a ...
Emcure Pharmaceuticals on Monday said it has signed a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. Under the agreement, effective April 1, ...
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a ...
Emcure partners with Roche to enhance access to nephrology and transplant therapies for chronic kidney disease in India.
AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the ...
Emcure Pharmaceuticals has announced the signing of a distribution agreement with Roche for select products in the nephrology ...
Emcure Pharma to distribute Roche's nephrology & transplant medicines in India. Aims to improve patient access & outcomes for CKD & transplant needs.
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
Late-stage study finds Roche's giredestrant shows no improvement over standard therapy in preventing cancer progression.
Emcure Pharmaceuticals today announced the signing of a distribution agreement with Roche for select products in the ...
For Roche's select brands in nephrology and transplant segment in India ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results